Skip to main content
Fig. 1 | Allergy, Asthma & Clinical Immunology

Fig. 1

From: Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey

Fig. 1

a Severity and b site of attacks by type of long-term prophylaxis (LTP). P values compared severity of attacks with LTP versus attacks without LTP. Attacks with a unknown severity and b unknown attack site were excluded. *Androgens include danazol, stanozolol, and oxandrolone. †Other includes all LTP treatments that combined >1 type of LTP

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us